Regeneron Pharmaceuticals, Inc. Stock price
Equities
REGN
US75886F1075
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
959.9 USD | -0.47% | -0.47% | +9.29% |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Financials (USD)
Sales 2024 * | 13.89B | Sales 2025 * | 14.87B | Capitalization | 103B |
---|---|---|---|---|---|
Net income 2024 * | 4.16B | Net income 2025 * | 4.56B | EV / Sales 2024 * | 6.79 x |
Net cash position 2024 * | 8.91B | Net cash position 2025 * | 12.78B | EV / Sales 2025 * | 6.08 x |
P/E ratio 2024 * |
26.1
x | P/E ratio 2025 * |
23.7
x | Employees | 13,450 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.18% |
Latest transcript on Regeneron Pharmaceuticals, Inc.
1 day | -0.47% | ||
1 week | -0.47% | ||
Current month | -0.64% | ||
1 month | +1.25% | ||
3 months | +12.82% | ||
6 months | +16.42% | ||
Current year | +9.29% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 64 | 88-01-07 | |
Chief Executive Officer | 71 | 88-01-07 | |
Director of Finance/CFO | 54 | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 10-11-11 |
Chief Executive Officer | 71 | 88-01-07 | |
Michael Brown
BRD | Director/Board Member | 82 | 91-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.27% | 0 M€ | 0.00% | - | |
7.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 959.9 | -0.47% | 360,302 |
24-03-15 | 964.5 | +0.57% | 1,090,502 |
24-03-14 | 959 | -0.67% | 507,315 |
24-03-13 | 965.5 | -0.53% | 386,222 |
24-03-12 | 970.6 | +0.64% | 359,030 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.29% | 103B | |
+1.10% | 106B | |
-2.74% | 21.44B | |
-11.89% | 22.11B | |
-26.59% | 20.99B | |
-5.34% | 19.44B | |
-6.58% | 17.6B | |
+5.83% | 13.88B | |
+7.46% | 11.75B | |
+28.56% | 11.64B |